← Metformin × all-cause mortality

TrialThe oncologist2019

Impact of Metformin Use and Diabetic Status During Adjuvant Fluoropyrimidine-Oxaliplatin Chemotherapy on the Outcome of Patients with Resected Colon Cancer: A TOSCA Study Subanalysis.

Claudio Vernieri et al.PubMed ↗Full text ↗Publisher ↗

  • Metformin useno clear effectNo clear link with overall survival.Correlation only, not a test of it.

What moved togetherboth groups pooled, not the treatment’s effect

Correlation · may be no link

No clear link with overall survival

1.5×0.5× to 4.8×

metformin use vs no metformin use, in patients with high-risk stage II or stage III colon cancer randomized in the TOSCA trial who had diabetes (T2DM)

Bigger than 8 in 10 for all-cause mortality

As reported

HR 1.51, 95% CI 0.48–4.77

Who was studied, and how

3,759people with type 2 diabetes, in this paper

Already taking metformin use, or nottheir own situation, not assigned

on metformin use
not on metformin use

No clear link with overall survival1.5×

correlation, not a test

the abstract, start to end

… with OS (adjusted hazard ratio [HR], 1.51; 95% confidence interval [CI], …

← favours treatmentfavours comparator →
could be chance
Overall survival (OS)metformin use vs no metformin use, in patients with high-risk stage II or stage III colon cancer randomized in the TOSCA trial who had diabetes (T2DM)
HR 1.510.48–4.77
MetforminAll-cause mortality
1 / 4

21 papers cite it

2019
2020
2021
2022
2023
2024
2025
2026
this paperpooled itcites it
Full record →Abstract, authors, funding and every citing paper · PMID 30606884